IS6571A - Samsett lyfjameðferð - Google Patents

Samsett lyfjameðferð

Info

Publication number
IS6571A
IS6571A IS6571A IS6571A IS6571A IS 6571 A IS6571 A IS 6571A IS 6571 A IS6571 A IS 6571A IS 6571 A IS6571 A IS 6571A IS 6571 A IS6571 A IS 6571A
Authority
IS
Iceland
Prior art keywords
combination chemotherapy
chemotherapy
combination
Prior art date
Application number
IS6571A
Other languages
English (en)
Inventor
Peart Smith Mark
Charles Stephens Trevor
Original Assignee
Anormed Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc. filed Critical Anormed Inc.
Publication of IS6571A publication Critical patent/IS6571A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6571A 2000-05-18 2002-09-27 Samsett lyfjameðferð IS6571A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0011903.2A GB0011903D0 (en) 2000-05-18 2000-05-18 Combination chemotherapy
PCT/GB2001/002060 WO2001087313A1 (en) 2000-05-18 2001-05-10 Combination chemotherapy

Publications (1)

Publication Number Publication Date
IS6571A true IS6571A (is) 2002-09-27

Family

ID=9891766

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6571A IS6571A (is) 2000-05-18 2002-09-27 Samsett lyfjameðferð

Country Status (28)

Country Link
US (1) US20040053882A1 (is)
EP (2) EP1530969A1 (is)
JP (2) JP2003533485A (is)
KR (2) KR20030014228A (is)
CN (3) CN101084886A (is)
AR (1) AR030281A1 (is)
AU (3) AU2001252442B8 (is)
BG (1) BG66113B1 (is)
BR (1) BR0110837A (is)
CA (1) CA2410067A1 (is)
CZ (1) CZ20023766A3 (is)
EE (1) EE05261B1 (is)
GB (1) GB0011903D0 (is)
HK (1) HK1049446A1 (is)
HU (1) HUP0302130A3 (is)
IL (1) IL151959A0 (is)
IS (1) IS6571A (is)
MX (1) MXPA02011247A (is)
MY (1) MY138923A (is)
NO (1) NO332079B1 (is)
NZ (1) NZ521632A (is)
PL (1) PL357721A1 (is)
RU (2) RU2429838C2 (is)
SK (1) SK16392002A3 (is)
TW (1) TW200637565A (is)
UA (1) UA81098C2 (is)
WO (1) WO2001087313A1 (is)
ZA (1) ZA200209279B (is)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US8791081B2 (en) * 1999-08-13 2014-07-29 Case Western Reserve University MGMT inhibitor combination for the treatment of neoplastic disorders
ATE345130T1 (de) * 2001-12-03 2006-12-15 Bayer Pharmaceuticals Corp Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
RU2273475C2 (ru) * 2004-04-06 2006-04-10 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Способ лечения диссеминированного колоректального рака
NZ563686A (en) * 2005-06-07 2011-07-29 Univ Yale Methods of treating cancer and other conditions or disease states using LFMAU and LDT
US7616481B2 (en) * 2005-12-28 2009-11-10 Sandisk Corporation Memories with alternate sensing techniques
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
RU2340336C1 (ru) * 2007-05-02 2008-12-10 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ комбинированного лечения немелкоклеточного рака легкого iii стадии
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
JP2010533714A (ja) * 2007-07-16 2010-10-28 ポニアード ファーマシューティカルズ， インコーポレイテッド ピコプラチンのための経口製剤
AU2009210656A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and cetuximab to treat colorectal cancer
CN101302235B (zh) * 2008-06-30 2011-06-01 昆明贵研药业有限公司 甲啶铂的提纯
US20130211384A1 (en) * 2010-07-28 2013-08-15 Fondazione Irccs Istituto Nazionale Dei Tumori Therapeutic agent, composition including said agent, implantable device and process for the treatment of cervical cancer and/or for the prevention of the formation of neoplasms in correspondence of the cervix in a human female genital system
KR101389072B1 (ko) * 2011-05-25 2014-04-23 가톨릭대학교 산학협력단 ＢＨＲＦ１ 발현 억제를 위한 ｓｉＲＮＡ 및 이를 포함하는 조성물
CA2994502C (en) * 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
EP4234035A3 (en) 2017-05-16 2023-11-15 Ability Pharmaceuticals S.A. A pharmaceutical combination for the treatment of a cancer
CN113694205B (zh) * 2021-09-23 2023-05-16 山东第一医科大学(山东省医学科学院) 5-ht受体抑制剂和顺铂在制备治疗肝癌的药物中的应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1432562A (en) * 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
US4329299A (en) * 1979-08-23 1982-05-11 Johnson, Matthey & Co., Limited Composition of matter containing platinum
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
GR75317B (is) * 1980-09-03 1984-07-13 Johnson Matthey Plc
US4533502A (en) * 1983-02-22 1985-08-06 Rochon Fernande D Platinum (II) compounds and their preparation
DE3582961D1 (de) * 1984-06-27 1991-07-04 Johnson Matthey Plc Platinkoordinationsverbindungen.
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
US4902797A (en) * 1986-12-18 1990-02-20 Shionogi & Co., Ltd. Ammine-alicyclic amine-platinum complexes and antitumor agents
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
CN1016693B (zh) * 1987-06-05 1992-05-20 北京工业大学 新顺铂铬合物的制备方法
GB9105037D0 (en) * 1991-03-09 1991-04-24 Johnson Matthey Plc Improvements in chemical compounds
US5244991A (en) * 1991-10-15 1993-09-14 Phillips Petroleum Company Olefin polymerization process
NZ245112A (en) * 1991-11-15 1995-07-26 Smithkline Beecham Corp Pharmaceutical composition comprising a camptothecin analog and a platinum coordination compound
EP0672181B1 (en) * 1992-04-01 2003-11-05 The Johns Hopkins University School Of Medicine Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor
FR2707988B1 (fr) * 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
US5624919A (en) * 1993-09-14 1997-04-29 The University Of Vermont And State Agricultural College Trans platinum (IV) complexes
GB9408218D0 (en) * 1994-04-26 1994-06-15 Johnson Matthey Plc Improvements in platinum complexes
WO1996001638A1 (en) * 1994-07-11 1996-01-25 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
CN1039813C (zh) * 1994-10-31 1998-09-16 西安五环(集团)股份有限公司 具抗癌效应的顺式-二氨-1,1-环戊二羧酸根合铂(ⅱ)的化合物及其合成方法
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9502799D0 (en) * 1995-02-14 1995-04-05 Johnson Matthey Plc Improvements in platinum complexes
CN1039588C (zh) * 1995-03-29 1998-08-26 邹娟 新的抗肿瘤铂络合物
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
JP2000515852A (ja) * 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
ES2202796T3 (es) * 1997-02-03 2004-04-01 Pfizer Products Inc. Derivados de acidos arilsulfonilaminohidroxamicos.
AU3961899A (en) * 1998-05-04 1999-11-23 Auckland Uniservices Limited Chemotherapeutic treatment
DE19847618A1 (de) * 1998-10-15 2000-04-20 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6235782B1 (en) * 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
US6413953B1 (en) * 1999-04-13 2002-07-02 Anormed Inc. Pt(IV) antitumor agent
DE60023859T2 (de) * 1999-04-13 2006-08-03 Anormed Inc., Langley Verfahren zur herstellung von amin-platin-komplexen
AU785115B2 (en) * 1999-10-18 2006-09-21 Emory University TMS1 compositions and methods of use
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US20020102301A1 (en) * 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
WO2001060370A1 (en) * 2000-02-16 2001-08-23 Yamanouchi Pharmaceutical Co., Ltd. Remedies for endothelin-induced diseases
EP1261356A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20020110601A1 (en) * 2000-03-31 2002-08-15 Roman Perez-Soler Antineoplastic platinum therapeutic method and composition
US7253209B2 (en) * 2000-08-11 2007-08-07 Dainippon Sumitomo Pharma Co., Ltd. Remedies for cisplatin-tolerant cancer
US6894049B1 (en) * 2000-10-04 2005-05-17 Anormed, Inc. Platinum complexes as antitumor agents
US6544962B1 (en) * 2000-11-02 2003-04-08 Matrix Pharmaceutical, Inc. Methods for treating cellular proliferative disorders
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
US6673370B2 (en) * 2001-05-15 2004-01-06 Biomedicines, Inc. Oxidized collagen formulations for use with non-compatible pharmaceutical agents
US20050009908A1 (en) * 2001-08-06 2005-01-13 Hedberg Pia Margaretha Cecilia Aqueous dispersion comprising stable nonoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
DE10141528B4 (de) * 2001-08-24 2006-08-10 Faustus Forschungs Cie. Translational Cancer Research Gmbh Platin(II)- und Platin(IV)-Komplexe und ihre Verwendung
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
US20060078618A1 (en) * 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
US7691833B2 (en) * 2002-03-01 2010-04-06 Trustees Of Dartmouth College Compositions and methods for preventing sporadic neoplasia in colon
US20040010553A1 (en) * 2002-07-15 2004-01-15 International Business Machines Corporation Peer to peer location based services
TWI272273B (en) * 2002-07-16 2007-02-01 Sonus Pharma Inc Platinum compounds
AU2003302314A1 (en) * 2002-08-02 2004-07-09 Transave, Inc. Platinum aggregates and process for producing the same
WO2004012680A2 (en) * 2002-08-06 2004-02-12 Lyotropic Therapeutics, Inc. Lipid-drug complexes in reversed liquid and liquid crystalline phases
AU2002951833A0 (en) * 2002-10-02 2002-10-24 Novogen Research Pty Ltd Compositions and therapeutic methods invloving platinum complexes
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
DE10256182A1 (de) * 2002-12-02 2004-06-24 Merck Patent Gmbh 2-Oxadiazolchromonderivate
ES2300672T3 (es) * 2003-04-30 2008-06-16 Merck Patent Gmbh Derivados de cromenona.
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
WO2005111024A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
TW200600091A (en) * 2004-05-21 2006-01-01 Telik Inc Sulfonylethyl phosphorodiamidates
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EP2298291A3 (en) * 2004-06-18 2011-08-03 Agennix USA Inc. Kinase inhibitors for treating cancers
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
JP2008513435A (ja) * 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
US20090065522A1 (en) * 2004-10-13 2009-03-12 Nadir Benouali Unit dose compliance monitoring and reporting device and system
WO2006071812A2 (en) * 2004-12-23 2006-07-06 H. Lee Moffitt Cancer Center And Research Institute Platinum iv complex inhibitor
US20090047365A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
US8106033B2 (en) * 2005-03-11 2012-01-31 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
PT1888550E (pt) * 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
KR101643416B1 (ko) * 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US20070122350A1 (en) * 2005-11-30 2007-05-31 Transave, Inc. Safe and effective methods of administering therapeutic agents
US8143236B2 (en) * 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
JP5564249B2 (ja) * 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
RU2009133447A (ru) * 2007-02-09 2011-03-20 Пониард Фармасьютикалз, Инк. (Us) Дозированная форма пикоплатина
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
JP2010529023A (ja) * 2007-05-31 2010-08-26 アセンタ セラピューティックス インコーポレイティッド 疾患の処置のためのゴシポールの律動的投薬法
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
JP5410434B2 (ja) * 2007-09-28 2014-02-05 バインド セラピューティックス インコーポレイテッド ナノ粒子を用いた癌細胞の標的化
AU2009210656A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and cetuximab to treat colorectal cancer

Also Published As

Publication number Publication date
CN101084886A (zh) 2007-12-12
NO20025502D0 (no) 2002-11-15
AU2001252442B2 (en) 2006-03-23
EP1283712A1 (en) 2003-02-19
RU2010117635A (ru) 2011-11-10
NO332079B1 (no) 2012-06-18
RU2006122350A (ru) 2008-01-10
BG107281A (bg) 2003-09-30
NO20025502L (no) 2002-11-15
CN100411628C (zh) 2008-08-20
ZA200209279B (en) 2004-02-16
UA81098C2 (uk) 2007-12-10
IL151959A0 (en) 2003-04-10
HUP0302130A3 (en) 2005-06-28
TW200637565A (en) 2006-11-01
CN101310719A (zh) 2008-11-26
AR030281A1 (es) 2003-08-20
AU2001252442B8 (en) 2006-05-04
KR20090040926A (ko) 2009-04-27
KR20030014228A (ko) 2003-02-15
RU2587013C2 (ru) 2016-06-10
BR0110837A (pt) 2003-03-11
EE05261B1 (et) 2010-02-15
AU5244201A (en) 2001-11-26
CN1429114A (zh) 2003-07-09
HUP0302130A2 (hu) 2003-11-28
JP2012062329A (ja) 2012-03-29
CZ20023766A3 (cs) 2003-03-12
RU2429838C2 (ru) 2011-09-27
BG66113B1 (bg) 2011-05-31
AU2006201008A1 (en) 2006-04-06
SK16392002A3 (sk) 2003-04-01
AU2006201008C1 (en) 2009-08-13
EE200200648A (et) 2004-06-15
NZ521632A (en) 2004-08-27
HK1049446A1 (zh) 2003-05-16
WO2001087313A1 (en) 2001-11-22
US20040053882A1 (en) 2004-03-18
GB0011903D0 (en) 2000-07-05
MY138923A (en) 2009-08-28
AU2006201008B2 (en) 2009-01-08
JP2003533485A (ja) 2003-11-11
CA2410067A1 (en) 2001-11-22
PL357721A1 (en) 2004-07-26
MXPA02011247A (es) 2004-08-19
EP1530969A1 (en) 2005-05-18

Similar Documents

Publication Publication Date Title
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATA2932001A (de) Schneefräse
NO20025502L (no) Kombinasjons kjemoterapi
DE50104056D1 (de) Gewichtsmanschette
DE50100710D1 (de) Wischblatt
ATE262530T1 (de) Indolochinazolinone
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50100817D1 (de) Kugelgelenk
DE50011511D1 (de) Blowby-Heizung
AR027931A1 (es) Antitranspirantes
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
DE50007634D1 (de) Kardioplegieballonkatheter
DE10052925B4 (de) Schaukelbett
ATE476423T1 (de) Benzoylpyridazine
DE10195909T1 (de) Viehfüttervorrichtung
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos
DE60143209D1 (de) Zweiport-demodulationseinrichtung
DE10195992T1 (de) Oberflächenendbearbeitungsbelag
ATE284887T1 (de) Thienopyrrolidinone